Novartis Venture Fund
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.
Business Model:
Revenue: $34.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Novartis Venture Fund Information
Geographic Data
Address: 355 Main St
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
9,316,027Website Global Rank
166Website Monthly Traffic
Twitter Followers
Description
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100&s;000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics &a; platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
Contact Phone:
+16178713536
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2004 | Nura | Series A | 9.5M |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 8/2018 | Artios Pharma | Series B | 0 |
| 10/2009 | Evolva | Series B | 27.8M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 5/2003 | GlycoMimetics | Series A | 4.3M |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 7/2011 | Myopowers Medical Technologies | Series B | 16M |
| 6/2015 | Myopowers Medical Technologies | Series C | 5.1M |
| 2/2012 | Celladon | Venture Round | 43M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 6/2015 | Realeve | Series D | 43.2M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 1/2018 | Oculis | Series B | 20.5M |
| 5/2001 | AGY | Series B | 13M |
| 9/2021 | Flywheel.io | Series C | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 5/2002 | Kalypsys | Series A | 42M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 5/2002 | ESBATech | Series A | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 6/2015 | Kanyos Bio | Venture Round | 16.4M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 5/2001 | Polyphor | Venture Round | 9.3M |
| 1/2010 | Merus | Series B | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 10/2002 | MerLion Pharma | Series A | 0 |
| 2/2006 | EyeSense AG | Series A | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 2/2007 | Trellis Bioscience | Series B | 10M |
| 2/2008 | Biofisica | Venture Round | 2.4M |
| 6/2007 | Tepha | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 5/2017 | Lemonaid Health | Series A | 0 |
| 10/2011 | Realeve | Series C | 32M |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 6/2010 | NanoPowers | Series A | 0 |
| 8/2021 | GentiBio | Series A | 157M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 10/2012 | Neurovance | Venture Round | 7M |
| 4/2014 | Neurovance | Series A | 6.3M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 11/2007 | Ascent Therapeutics | Series A | 19M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 9/2020 | Novellus | Series C | 57M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 9/2009 | PharmAbcine | Series A | 6M |
| 1/2000 | Viron Therapeutics | Series A | - |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 8/2004 | GlycoMimetics | Series A | 5.1M |
| 2/2016 | Galera Therapeutics | Series B | 0 |
| 8/2014 | Galera Therapeutics | Series A | 4.7M |
| 6/2006 | GlycoMimetics | Series B | 0 |
| 7/2017 | NeuroVia | Series A | 14M |
| 3/2007 | Phenomix | Series C | 55M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2007 | Aileron Therapeutics | Series B | 7M |
| 10/2013 | Opsona | Series C | 0 |
| 6/2009 | Alios BioPharma | Series A | 24M |
| 7/2009 | Avila Therapeutics | Series B | 30M |
| 4/2012 | Advanced Animal Diagnostics | Series B | 4M |
| 5/2009 | NovImmune | Venture Round | 0 |
| 4/2007 | Protemix | Series A | 14.5M |
| 6/2009 | Opsona | Series B | 4.6M |
| 9/2016 | Inflazome | Series A | 17M |
| 4/2013 | Opsona | Series C | 0 |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 3/2022 | Epsilogen | Series B | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 4/2008 | Aileron Therapeutics | Series C | 10.5M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 8/2004 | Evolva | Series A | 14.8M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 11/2022 | DJEL | Venture Round | 139.4M |
| 10/2009 | Covagen | Seed Round | - |
| 11/2010 | Covagen | Series A | 6.3M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 3/2005 | Evolva | Series A | 2.6M |
| 7/2009 | Intellikine | Series B | 51M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 6/2007 | Cequent Pharmaceuticals | Series A | 9M |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 11/2020 | Catalym | Series B | 59.3M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 1/2015 | Binx Health | Series C | 0 |
| 9/2011 | Eledon Pharmaceuticals | Series D | 23M |
| 3/2011 | Euthymics Bioscience | Series A | 4M |
| 8/2006 | ESBATech | Series B | 41M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 12/2006 | Evolva | Series A | 10.3M |
| 12/2008 | Diagnoplex | Series A | 8.3M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 4/2011 | ProCertus BioPharm | Series A | 1.7M |
| 8/2010 | Anchor Therapeutics | Series B | 10M |
| 4/2008 | FORMA Therapeutics | Series A | 4M |
| 1/2016 | Adicet Bio | Series A | 51M |
| 2/2007 | Omeros | Series E | 0 |
| 3/2015 | Galera Therapeutics | Series A | 4.7M |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 3/2010 | Immune Targeting Systems | Series A | 13.2M |
| 6/2006 | NovImmune | Series B | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 3/2012 | ImaginAb | Series A | 12.5M |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 10/2009 | Bicycle Therapeutics | Seed Round | - |
| 10/2014 | Quartet Medicine | Series A | 17M |
| 10/2013 | Merus | Series B | 42.2M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 1/2010 | MicroCHIPS | Venture Round | 16.5M |
| 8/2014 | YourBio Health | Series B | 16M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 5/2019 | Cala Health | Series C | 0 |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 12/2012 | Galera Therapeutics | Series A | 11M |
| 3/2020 | Akouos | Series B | 105M |
| 8/2018 | Akouos | Series A | 25.1M |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 11/2009 | Oxagen | Series C | 0 |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 5/2015 | Realeve | Series D | 38M |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 7/2019 | TScan Therapeutics | Series B | - |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 7/2009 | Symetis | Series B | 0 |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 3/2011 | Advanced Animal Diagnostics | Series B | 11M |
| 4/2014 | Binx Health | Series B | 0 |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 4/2007 | MicroCHIPS | Venture Round | 13.4M |
| 9/2019 | Anokion | Series B | 40M |
| 12/2019 | Arctos Medical | Seed Round | 0 |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 5/2009 | Visiogen | Series D | 40M |
| 12/2020 | Exo Therapeutics | Series A | 25M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 9/2012 | F2G | Equity | 30M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 2/2005 | Covalys Biosciences | Series B | 2.6M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 8/2020 | GentiBio | Seed Round | 20M |
| 11/2004 | Symetis | Series A | 9.6M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 5/2013 | Eledon Pharmaceuticals | Series E | 35.5M |
| 5/2000 | NovImmune | Series A | 14M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 6/2016 | F2G | Series E | 60M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 9/2016 | Rox Medical | Series E | 40M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 12/2006 | Aileron Therapeutics | Series A | 7M |
| 4/2013 | Advanced Animal Diagnostics | Series B | 6M |
| 5/2014 | ImaginAb | Series B | 21M |
| 1/2019 | Occlufit | Venture Round | - |
| 2/2015 | Altimmune | Post-IPO Equity | 16M |
| 7/2010 | Euthymics Bioscience | Series A | 24M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 10/2015 | Galera Therapeutics | Series B | 37M |
| 8/2019 | Renovacor | Series A | 11M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 5/2007 | ProCertus BioPharm | Series A | 2.3M |
| 7/2009 | ProCertus BioPharm | Venture Round | 2.1M |
| 2/2009 | Alios BioPharma | Series A | 8.4M |
| 7/2001 | Nereus Pharmaceuticals | Series B | 23.6M |
| 10/2006 | Biofisica | Series A | 5M |
| 7/2007 | Neovacs | Venture Round | 17.9M |
| 1/2006 | EraGen Biosciences | Series A | 12M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 6/2009 | Eledon Pharmaceuticals | Series D | 22M |
| 7/2007 | Immune Targeting Systems | Series A | 7.1M |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 10/2012 | Thesan Pharmaceuticals | Series A | 16M |
| 5/2020 | mPharma | Series C | 0 |
| 2/2019 | Anaveon | Series A | 35M |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 3/2022 | Epsilogen | Series B | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
